Model-based drug development: the road to quantitative pharmacology (Q34537529)

2 August 2017

Model-based drug development: the road to quantitative pharmacology (English)

1 reference

2 August 2017

1 reference

Liping Zhang

1

1 reference

2 August 2017

Vikram Sinha

2

1 reference

2 August 2017

S Thomas Forgue

3

1 reference

2 August 2017

Sophie Callies

4

1 reference

2 August 2017

Lan Ni

5

1 reference

2 August 2017

Richard Peck

6

1 reference

2 August 2017

Sandra R B Allerheiligen

7

1 reference

2 August 2017

13 June 2006

1 reference

Journal of Pharmacokinetics and Pharmacodynamics

2 August 2017

1 reference

2 August 2017

33

1 reference

2 August 2017

3

1 reference

2 August 2017

369-393

1 reference

https://scigraph.springernature.com/pub.10.1007/s10928-006-9010-8

2 August 2017

0 references

cites work

Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions.

1 reference

12 December 2020

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

1 reference

12 December 2020

Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation

1 reference

12 December 2020

Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience

1 reference

12 December 2020

Prediction of growth factor effects on engineered cartilage composition using deterministic and stochastic modeling

1 reference

12 December 2020

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

12 December 2020

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

1 reference

12 December 2020

Drug treatment effects on disease progression.

1 reference

12 December 2020

Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making

1 reference

12 December 2020

Disease system analysis: basic disease progression models in degenerative disease

1 reference

12 December 2020

Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective

1 reference

12 December 2020

Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection.

1 reference

12 December 2020

Physiologic indirect response models characterize diverse types of pharmacodynamic effects

1 reference

12 December 2020

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic studies in drug product development

1 reference

12 December 2020

Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia

1 reference

12 December 2020

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics in the development of antifungal compounds.

1 reference

12 December 2020

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

1 reference

12 December 2020

Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

1 reference

12 December 2020

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

1 reference

12 December 2020

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients

1 reference

12 December 2020

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

1 reference

12 December 2020

Modelling during drug development

1 reference

12 December 2020

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors

1 reference

12 December 2020

Model-based approaches to biomarker discovery and evaluation: a multidisciplinary integrated review

1 reference

12 December 2020

Biological simulations in drug discovery

1 reference

12 December 2020

Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans

1 reference

12 December 2020

Against the proposition: all patients with advanced HIV disease should be offered rifabutin prophylaxis

1 reference

12 December 2020

Expanding clinical applications of population pharmacodynamic modelling

1 reference

12 December 2020

Model-based development of gemcabene, a new lipid-altering agent

1 reference

12 December 2020

Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma

1 reference

12 December 2020

The importance of pharmacokinetic limited sampling models for childhood cancer drug development

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic modeling in drug development

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic modelling in oncological drug development

1 reference

12 December 2020

Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man

1 reference

12 December 2020

Predictive biosimulation and virtual patients in pharmaceutical R and D

1 reference

12 December 2020

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

1 reference

12 December 2020

Learning versus confirming in clinical drug development

1 reference

12 December 2020

10.1007/S10928-006-9010-8

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference